The primary objective was to determine the prevalence of cochlear (C-DF) and vestibular (V-DF) dysfunction in patients with CF at LHSC. Secondary objectives included determining if there is an association between aminoglycoside (AMG) exposure or other risk factors and ototoxicity in CF patients. Methods: 73 patients with C-DF and V-DF are needed to detect a 0−10% prevalence rate with 95% confidence. Patients with a diagnosis of CF were eligible for study enrollment. Study participants completed audiometric testing to detect C-DF. V-DF was detected by completing five standard balance tests. Additional risk factors for ototoxicity, including AMG exposure, were investigated. Results: 49 patients (1−48 years of age) completed audiometric testing and 37 patients completed balance testing. Of these, 4 (8.9%) patients had C-DF and 20 (54.1%) patients had V-DF. There was no statistically significant difference in the rate of C-DF and V-DF in patients exposed to AMG as compared to those not exposed (C-DF, P = 0.812; V-DF, P = 0.051). Family history of hearing loss, prematurity, loud noise exposure, or ototoxic medication use did not produce statistically significant higher rates of C-DF and V-DF.
Objectives: Aminoglycoside antibiotics, commonly used for the treatment of pulmonary exacerbations in cystic fibrosis, are potentially toxic to renal proximal tubule epithelial cells. A novel urinary biomarker, Kidney Injury Molecule-1 (KIM-1), has specificity for proximal tubule injury. The aim of this study was to assess KIM-1 as a biomarker of aminoglycoside-induced nephrotoxicity in children with cystic fibrosis. Methods: Baseline urine samples were collected from 44 children aged 0−16 years with cystic fibrosis, and before, during and after exposure to tobramycin in 10 of these children. KIM-1 was measured using a Meso Scale Discovery analytical platform, and standardised to urinary creatinine. Results: Mean baseline KIM-1 was 0.57 ng/mg Cr (95% Confidence Interval (CI), 0.40-0.73 ng/mg Cr, n = 44). There was a significant correlation between baseline KIM-1 and the number of previous courses of aminoglycosides (R=0.70, P < 0.002). During exposure to tobramycin mean peak KIM-1 was significantly elevated from baseline (mean peak KIM-1, 1.24 ng/mg Cr, 95% CI, 0.71-1.78 ng/mg Cr, p = 0.02, n = 10). Mean fold change [(peak KIM-1 during tobramycin exposure)/ (pre-treatment baseline KIM-1)] was 3.03 (95% CI, 1.89-4.17).
Conclusion:
In children with cystic fibrosis we have demonstrated significant acute changes in urinary KIM-1 during exposure to tobramycin, and an association of baseline KIM-1 with previous aminoglycoside exposure. KIM-1 may be a useful, non-invasive, biomarker of acute and chronic proximal tubular injury associated with exposure to aminoglycosides in children with cystic fibrosis. 
